| Literature DB >> 35215302 |
Fouad Damiri1, Nagavendra Kommineni2, Samuel Ogbeide Ebhodaghe3, Raviteja Bulusu4, Vaskuri G S Sainaga Jyothi5, Amany A Sayed6, Aeshah A Awaji7, Mousa O Germoush8, Hamdan S Al-Malky9, Mohammed Z Nasrullah10, Md Habibur Rahman11, Mohamed M Abdel-Daim12,13, Mohammed Berrada1.
Abstract
In this focused progress review, the most widely accepted methods of transdermal drug delivery are hypodermic needles, transdermal patches and topical creams. However, microneedles (MNs) (or microneedle arrays) are low-invasive 3D biomedical constructs that bypass the skin barrier and produce systemic and localized pharmacological effects. In the past, biomaterials such as carbohydrates, due to their physicochemical properties, have been extensively used to manufacture microneedles (MNs). Due to their wide range of functional groups, carbohydrates enable the design and development of tunable properties and functionalities. In recent years, numerous microneedle products have emerged on the market, although much research needs to be undertaken to overcome the various challenges before the successful introduction of microneedles into the market. As a result, carbohydrate-based microarrays have a high potential to achieve a future step in sensing, drug delivery, and biologics restitution. In this review, a comprehensive overview of carbohydrates such as hyaluronic acid, chitin, chitosan, chondroitin sulfate, cellulose and starch is discussed systematically. It also discusses the various drug delivery strategies and mechanical properties of biomaterial-based MNs, the progress made so far in the clinical translation of carbohydrate-based MNs, and the promotional opportunities for their commercialization. In conclusion, the article summarizes the future perspectives of carbohydrate-based MNs, which are considered as the new class of topical drug delivery systems.Entities:
Keywords: microneedles; natural polysaccharide; sustained and controlled release; transdermal drug delivery
Year: 2022 PMID: 35215302 PMCID: PMC8875238 DOI: 10.3390/ph15020190
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1Characteristic features to be considered during the preparation of microneedles.
Thedecision matrix for the design of suitable microneedles on the following performances presenting as low efficacy (✖), moderate efficacy (▲), and high efficacy (🞅). Reprinted from ref. [21].
| MicroneedleType | Solid Microneedle | Coated Microneedle | Dissolving Microneedle | Hydrogel Microneedle | |
|---|---|---|---|---|---|
| DecisionParameter | |||||
| Drug dose | 🞅 High | ✖ Low | ✖ Low | 🞅 High | |
| Onset of action (Pharmacokinetics/ pharmacodynamics) | ✖ | 🞅 | 🞅 | ✖ | |
| Delivery period | ▲ Several hours (agents that keep the pores open longer are additionally needed) | ✖ | 🞅 | ▲ Several hours | |
| Delivery efficiency (Expensive drugs require high delivery efficiency) | ✖ | 🞅 | 🞅 | ✖ | |
| Sharp waste generation | 🞅 | 🞅 | ✖ | ▲ Swollen hydrogel microneedle tip | |
| Packaging | ▲ Separate packaging for microneedles and formulation | 🞅 | 🞅 | 🞅 | |
| Patch-wearing time | ✖ | 🞅 | 🞅 | ✖ | |
Type of microneedle system.
| Microneedle | Material | Technique Employed | Approach | Type of Product | Improvements | References |
|---|---|---|---|---|---|---|
| Solid Microneedles | Silicon | Dry and Wet Etching | Poke and Patch | Docetaxel Liposomes | Skin permeation | [ |
| Derma-roller | NA | Topical 5-FU | Invitro and in vivo anti-tumor activity | [ | ||
| MNs coated with ZnONanowires | Photolithography | Paclitaxel | 10% increase in reduction of tumor size compared to conventional method | [ | ||
| Stainless Steel | - | Combinational (Mesoporous Nano Particles) Therapy of Phthalocyanine, Dabrafenib, Trametinib | Inhibited cell proliferation and anti-tumor activity by reactive oxygen species | [ | ||
| Coated Microneedles | Stainless Steel | Infrared Laser | Coat and Poke | 5-FU, Curcumin and Cisplatin | Ink-jet printing on SS Microneedles | [ |
| Stainless Steel | Wet Etching | PLGA Nanoparticles of DOX | Effective local delivery for oral cancer | [ | ||
| Stainless Steel | Manual Coating | Octa-Arginine siRNA Nanocomplexes | Induced BRAF gene, which is responsible for melanoma development, induce tumor apoptosis and proliferation | [ | ||
| Polycarbonate | Dip Coating | Immunotherapy using DNA Polyplexes and Poly Adjuvant | Induced humoral and cellular immunity facilitated targeting and activation of skin | [ | ||
| Hallow Microneedles | Nickel | - | Poke and Flow | DOX | Increased drug diffusion coefficient | [ |
| Stainless Steel | - | 5-FU | Effective against gastric cancer cells | [ | ||
| Silicon | Manual Coating | HPV 16 E6 siRNA | Targeted delivery and inhibited tumor progression and observed no major adverse reactions | [ | ||
| Dissolving Microneedles | Polyvinyl Alcohol | Micro Molding | Poke and Dissolve | DOX | Improved permeation | [ |
| Zein | Micro Molding | Tamoxifen and Gemcitabine | No improvement for tamoxifen, observed great permeation in gemcitabine | [ | ||
| Sodium CMC | Micro Molding | Lipid-XoatedCisplatin Nanoparticles | Enhanced cytotoxicity and reduced tumor size | [ | ||
| Pluronic F127 | Micro Molding | Cancer Vaccination for EG7-OVA Tumor | Improved antigen-specific humoral and cellular immunity | [ | ||
| Hydrogel Microneedles | PLGA | Multiple Casting | Poke and Swell | Amphotericin | Controlled, prolonged release of drug for a week | [ |
| Ethylene Glycol | Molding | Metformin HCl | Sustained release | [ | ||
| PEG-PMVE/MA | Micro Molding | Anti-Microbial | No microbial invasion through skin | [ |
Figure 2Schematic representation of drug flow of different microneedles.
Figure 3Mechanism of drug delivery by microneedle device: (1) microneedle device with drug solution; (2) device inserted into the skin; (3) temporary mechanical disruption of the skin; (4) release of drug into the epidermis; (5) transport of drug to the site of action. Reprinted with permission from Ref. [19]. Copyright 2019 Elsevier.
Figure 4Advantages and sources of natural polysaccharides used in the fabrication of microneedles.
Summary of polysaccharides used for the preparation of microneedles.
| Polysaccharide | Source | Monosaccharide Units | Type of Microneedle Fabricated | Inference | Reference |
|---|---|---|---|---|---|
| Chitosan | Derived from chitin (natural sources of crustacean family) | Hollow–solid, dissolving, and coated layer-by-layer microneedles | Possess good mechanical strength and also availed for its adjuvant and antibacterial property | [ | |
| Hyaluronic acid | Rooster combs, shark skin | Hollow, dissolving and hydrogel microneedle | Self-dissolving ability and good penetration | [ | |
| Chondroitin sulfate | Cartilage, porcine skin and bovine trachea | N-acetyl-galactosamine and | Dissolving microneedle | Good penetration | [ |
| Alginate | Brown algae | α- | Dissolving microneedle | High mechanical strength when combined with maltose | [ |
| Xanthan gum | Xanthomonas campestris | β-(1,4)- | Coated microneedles | Used as viscosity enhancer for coated microneedles | [ |
| Starch | Corn or potato | Glucose | Dissolving microneedle | Owing to its brittleness blended with gelatin | [ |
| Pullulan | Aureobasidiumpullulans | Maltose | Dissolving microneedle | Exhibited good mechanical properties | [ |
| Bletilla striata | Bletilla striata | α-mannose, β-mannose, and β-glucose | Dissolving microneedle | Good mechanical strength and sufficient penetrating ability | [ |
| Panaxnotoginseng | Panaxnotoginseng | Backbone of→4)-α- | Dissolving microneedle | Good loading capacity and compatible with hydrophilic and lipophilic molecules, producing sustained and stable drug release | [ |
Figure 5(a) Image of the flexible MAE, (b) Image of the flexible MAE on the curved skin (c) SEM image of the flexible MAE, and (d) SEM image of a microneedle (MN). Reprinted with permission from Ref. [159]. Copyright 2019 MDPI.